The effects of pyridium in certain urogenital infections

Kirwin, Thomas J.; Lowsley, Oswald S.; Menning, Joseph H.

doi:10.1016/s0002-9610(43)90050-9

Cited by 9 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a longer duration of phenazopyridine was utilized in this study, the lack of well-defined methods for capturing efficacy or safety events is a major limitation. 10 While both Kirwin et al and Gould provide some perspective on the ADR profile of phenazopyridine, neither study addresses the safety of use beyond 14 days or includes patients with radiation cystitis. 9,10 Limitations This study was limited by its retrospective design and the limited availability of laboratory data during the time of presumed drug exposure.…”

Section: Discussionmentioning

confidence: 99%

“…10 While both Kirwin et al and Gould provide some perspective on the ADR profile of phenazopyridine, neither study addresses the safety of use beyond 14 days or includes patients with radiation cystitis. 9,10 Limitations This study was limited by its retrospective design and the limited availability of laboratory data during the time of presumed drug exposure. However, the posthoc sensitivity analysis demonstrated similar results among patients with the most appropriately timed data set.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety analysis of long-term phenazopyridine use for radiation cystitis

Shore

Britnell

Brown

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Phenazopyridine is a urinary tract analgesic indicated for short-term treatment of irritation in the lower urinary tract. Despite the lack of evidence for extended use, it is often used in varying durations for supportive care for cancer patients with radiation-induced cystitis. The objective of this study was to compare the incidence of adverse drug reactions in patients with radiation cystitis receiving long-term phenazopyridine (>14-day supply) compared to a matched comparator group. Methods This retrospective cohort study compared adverse events among cancer patients with and without phenazopyridine exposure. Included patients received radiation and at least one chronic medication between 1 July 2008 and 30 June 2017. The phenazopyridine group also received >14-day supply of phenazopyridine during the study period. Patients were matched based on gender, age (±5 years), cancer diagnosis, and palliative or curative treatment intent. Data collection occurred at baseline, during the time of presumed exposure, and through the end of the study period for surveillance purposes. Results A total of 272 patients received phenazopyridine for >14-day supply during the study period. Of these, 90 patients were included and matched to an equal number of patients in the comparator group. The included patients were similar between groups and were largely male with a diagnosis of prostate cancer. Most patients received between a 30- and 60-day supply of phenazopyridine. There were a total of 13 adverse drug reactions in the phenazopyridine group and 18 in the comparator group ( p = 0.32). No differences were identified between the phenazopyridine and comparator groups for the incidence of individual adverse drug reactions, emergency department visits, hospitalizations, or new diagnoses of hepatocellular or colorectal cancer. Conclusion There was no difference in adverse drug reactions among patients receiving phenazopyridine for >14 days compared to a matched comparator group. The overall incidence of adverse events in both groups was low.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Safety analysis of long-term phenazopyridine use for radiation cystitis

Shore

Britnell

Brown

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…На яркое окрашивание мочи в оранжевый цвет обратили внимание 11 (9,8%) пациенток, однако это не считается побочным эффектом терапии [15][16][17][18][19]. Серьезных нежелательных явлений приема каждым пациентом 1200 мг феназопиридина не зафиксировано.…”

Section: Dynamics Of the Acss Scale Indexes Pointsunclassified

“…пациентов [14]. Хорошие результаты опубликовали в 1943 г. T.J. Kirwin и соавт., успешно пролечившие 118 больных [15].…”

unclassified

Analgesic and antidysuric effects of phenazopyridine in the treatment of acute uncomplicated cystitis: results of a 3-year study.

Давидов¹,

Meltsina²,

Bunova³

et al. 2023

ECU

View full text Add to dashboard Cite

Introduction. Currently, there is a renaissance of phenazopyridine in world urology. The aim of this work was to study the analgesic and antidysuric effects of phenazopyridine, as well as to evaluate the efficacy and tolerability of phenazopyridine in combination with fosfomycin for the treatment of acute uncomplicated cystitis in women of working age. Materials and methods. In 2020–2022 a multicenter randomized open study was conducted. This study involved 224 women aged 18 to 60 years with acute uncomplicated cystitis. They were randomized into two groups of 112 people each. In the first group, patients received oral phenazopyridine (Urinalgin F, earlier Fenazalgin) 200 mg 3 times a day for 2 days (total dose 1200 mg) and fosfomycin trometamol (Monural) at a dose of 3 g once. In the 2nd group, women received orally once 3 g of fosfomycin trometamol and drotaverine hydrochloride (No-spa) 80 mg 3 times a day for 2 days. The visual analogue scale (VAS) of pain, the assessment of symptoms of cystitis according to the ACSS scale, urinalysis by microscopy, and bacteriological examination of urine were used. The results were evaluated after 6, 12, 24 and 48 hours, 3 and 6 days. Results. In the 1st group, a strong uroanalgesic and antidysuric effect of phenazopyridine was revealed. According to VAS, the severity of pain decreased from the initial 7.3±0.5 points after 6 hours to 3.7±0.4 points, after 12 hours to 1.6 points, after 24 hours to 0.4 points, and after 48 hours the pain disappeared in all 112 patients. The sum of the characteristic symptoms of cystitis on the ACSS scale from the initial 12.2±0.5 points decreased to 2.1±0.2 points after 3 days, and to 0.27±0.04 points after 6 days. In patients of the 2nd group, for all indicators, a less pronounced symptomatic effect was obtained with relief of pain and dysuria. The combined treatment of cystitis with fosfomycin and phenazopyridine turned out to be more effective than the combination of fosfomycin and drotaverine hydrochloride: in the 1st group, 97.3% of patients recovered, bacteriological efficiency was 96.8%, leukocyturia disappeared at an earlier date, by 30% reduced treatment time. An undesirable effect of phenazopyridine (nausea) was detected in 1 (0.9%) patient. Сonclusion. Phenazopyridine has a pronounced uroanalgesic and antidysuric effect and is an effective and safe agent for the symptomatic treatment of patients with acute uncomplicated cystitis. The combination of the antibiotic fosfomycin and the uroanalgesic phenazopyridine improves the results of the treatment of acute uncomplicated cystitis, has a clinical efficacy of 97.3% and a bacteriological efficacy of 96.8%.

show abstract

“…A new medication 1 containing adequate amounts of 3 pharmacologically active preparations in tablet form has recently been introduced and recommended for this purpose. Each tablet contains 150 mg of phenazopyridine hydrochloride [reported to have an anesthetic effect on the bladder mucosa (1, 2), thereby providing rapid relief of pain and burning caused by irritation]; 0.3 mg of l ‐hyoscyamine [a smooth muscle relaxant with a peripheral activity twice that of atropine (3, 4), for the control of spasm]; and 15 mg of butabarbital sodium [a mild nervous‐system depressant with an intermediate duration of action (5), for the control of anxiety and apprehension].…”

mentioning

confidence: 99%

A New Medication for Relief of Urinary Symptoms: A Preliminary Report

Spinelli¹,

Keshin²,

Davis³

1964

J American Geriatrics Society

View full text Add to dashboard Cite

The syndrome of burning, frequency, urgency and nocturia in urogenital infections and noninfective disease states, and as a sequel to surgical procedures (including instrumentation), is of common occurrence. The association with diverse urogenital disorders, especially in geriatric patients, suggests a common disturbance of the physiologic mechanisms of voiding. Since the relief of symptoms is of paramount importance to the patient, much effort has been expended to find a suitable agent for this purpose. Such an agent should: 1) relieve spasm, 2) relax the detrusor, 3) minimize local symptoms of frequency, urgency and burning, and 4) allay apprehension and anxiety which, in many elderly patients, may contribute to the perpetuation of symptoms.

show abstract

The effects of pyridium in certain urogenital infections

Cited by 9 publications

References 4 publications

Safety analysis of long-term phenazopyridine use for radiation cystitis

Safety analysis of long-term phenazopyridine use for radiation cystitis

Analgesic and antidysuric effects of phenazopyridine in the treatment of acute uncomplicated cystitis: results of a 3-year study.

A New Medication for Relief of Urinary Symptoms: A Preliminary Report

Contact Info

Product

Resources

About